Last reviewed · How we verify
NCT06583109
Prediction Model of Treatment Efficacy for Age-related Macular Degeneration Based on Multi-source Imaging Modalities
trial in Age-related Macular Degeneration (ARMD) in 2,600 participants. Not yet recruiting.
1 January 2026
Quick facts
| Lead sponsor | Beijing Hospital |
|---|---|
| Status | Not yet recruiting |
| Study type | OBSERVATIONAL |
| Enrollment | 2,600 |
| Start date | 1 October 2024 |
| Primary completion | 1 January 2026 |
| Estimated completion | 1 June 2026 |
Conditions studied
- Age-related Macular Degeneration (ARMD) — all drugs for Age-related Macular Degeneration (ARMD) →
Sponsor
Beijing Hospital
Who can join
50 and older, any sex, with Age-related Macular Degeneration (ARMD). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Age-related macular degeneration (AMD) is one of the main causes of blindness in the elderly population. Intraocular injection of anti-VEGF drugs for neovascular AMD (nAMD) is the main treatment method at present. However, patients have different responses to anti-VEGF therapy, and some patients do not respond well to short - and long-term treatment. In this study, a retrospective study was adopted to collate and analyze the clinical data and imaging data of nAMD in the past, and to extract the imaging features from the multimodal modalities before and after treatment for deep learning, and to evaluate and quantify the clinical features, and to construct two multi-source feature models for predicting the short-term and long-term prognosis of nAMD patients. By verifying the accuracy of the model to predict the curative effect, the classification efficiency of the above characteristic models was compared, and the optimal model was selected. Its clinical application value was evaluated by calibration curve and decision curve. In addition, patients with poor treatment response in the study cohort were retrospectively analyzed, and the efficacy and safety of the combination of other treatment options in the actual clinic were analyzed. The purpose of this study is to provide scientific basis for early prediction, dynamic monitoring and optimization of overall treatment strategies for nAMD.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06583109
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Age-related Macular Degeneration (ARMD)
Currently open trials in the same condition.
- NCT06662162 — Microcurrent Stimulation Therapy for Intermediate to Advanced Nonexudative Age-related Macular Degeneration · NA · recruiting
- NCT06683950 — Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment · Phase 4 · recruiting
Other Beijing Hospital trials
Trials by the same sponsor.
- NCT07523724 — Screening and Management of Adults With Asthma and Allergic Diseases · NA · not yet recruiting
- NCT07398430 — Metabolic Characteristics and Prognostic Model of Acute Coronary Syndrome Complicated With Obstructive Sleep Apnea · not yet recruiting
- NCT07295665 — External Validation of Ischemia and Hemorrhage Risk Models in Patients With Coronary Heart Disease · not yet recruiting
- NCT07143851 — Multi-modal Intelligent Diagnosis System for Multiple Ophthalmic Diseases · not yet recruiting
- NCT06955819 — GUTPROH: Probiotic-Herbal Formula for Self-Reported Constipation in Community Adults · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06583109 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Beijing Hospital
- Last refreshed: 3 September 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06583109.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing